Cynata Therapeutics Limited
Cynata Therapeutics Limited, together with its subsidiaries, engages in the development and commercialization of proprietary induced pluripotent stem cell and mesenchymal stem cell technology under the Cymerus brand for human therapeutic use in Australia. The company's lead therapeutic product candidate is CYP-001, which has completed Phase 2 clinical trial for the treatment of graft versus host … Read more
Market Cap & Net Worth: Cynata Therapeutics Limited (CYYNF)
Cynata Therapeutics Limited (PINK:CYYNF) has a market capitalization of $32.53 Million ($32.53 Million) as of March 18, 2026. Listed on the PINK stock exchange, this USA-based company holds position #24428 globally and #8442 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Cynata Therapeutics Limited's stock price $0.14 by its total outstanding shares 237454369 (237.45 Million).
Cynata Therapeutics Limited Market Cap History: 2015 to 2025
Cynata Therapeutics Limited's market capitalization history from 2015 to 2025. Data shows change from $68.86 Million to $32.53 Million (-8.94% CAGR).
Cynata Therapeutics Limited Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Cynata Therapeutics Limited's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
17.26x
Cynata Therapeutics Limited's market cap is 17.26 times its annual revenue
1728.56x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $73.61 Million | $1.10 Million | -$4.94 Million | 66.94x | N/A |
| 2017 | $113.98 Million | $1.75 Million | -$4.55 Million | 65.17x | N/A |
| 2018 | $178.09 Million | $1.38 Million | -$4.57 Million | 129.51x | N/A |
| 2019 | $170.97 Million | $1.31 Million | -$8.47 Million | 130.65x | N/A |
| 2020 | $113.98 Million | $7.01 Million | -$3.64 Million | 16.26x | N/A |
| 2021 | $71.24 Million | $1.55 Million | -$7.69 Million | 46.08x | N/A |
| 2022 | $71.24 Million | $7.77 Million | -$5.45 Million | 9.17x | N/A |
| 2023 | $17.10 Million | $1.65 Million | -$14.28 Million | 10.33x | N/A |
| 2024 | $45.12 Million | $2.32 Million | -$9.74 Million | 19.48x | N/A |
| 2025 | $32.53 Million | $1.89 Million | -$9.39 Million | 17.26x | N/A |
Competitor Companies of CYYNF by Market Capitalization
Companies near Cynata Therapeutics Limited in the global market cap rankings as of March 18, 2026.
Key companies related to Cynata Therapeutics Limited by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #162 globally with a market cap of $117.09 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #281 globally with a market cap of $74.80 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #344 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #500 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #162 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $117.09 Billion | $462.49 |
| #281 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $74.80 Billion | $759.05 |
| #344 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #500 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Cynata Therapeutics Limited Historical Marketcap From 2015 to 2025
Between 2015 and today, Cynata Therapeutics Limited's market cap moved from $68.86 Million to $ 32.53 Million, with a yearly change of -8.94%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2025 | $32.53 Million | -27.89% |
| 2024 | $45.12 Million | +163.89% |
| 2023 | $17.10 Million | -76.00% |
| 2022 | $71.24 Million | 0.00% |
| 2021 | $71.24 Million | -37.50% |
| 2020 | $113.98 Million | -33.33% |
| 2019 | $170.97 Million | -4.00% |
| 2018 | $178.09 Million | +56.25% |
| 2017 | $113.98 Million | +54.84% |
| 2016 | $73.61 Million | +6.90% |
| 2015 | $68.86 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 18th, 2026 the market cap of Cynata Therapeutics Limited was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $32.53 Million USD |
| MoneyControl | $32.53 Million USD |
| MarketWatch | $32.53 Million USD |
| marketcap.company | $32.53 Million USD |
| Reuters | $32.53 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.